AR019415A1 - DERIVATIVES OF BIFENYLL, A PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT IN THE PREPARATION OF MEDICINES, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCEDURE TO PREPARE THESE PHARMACEUTICAL COMPOSITIONS - Google Patents
DERIVATIVES OF BIFENYLL, A PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT IN THE PREPARATION OF MEDICINES, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCEDURE TO PREPARE THESE PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- AR019415A1 AR019415A1 ARP990103510A ARP990103510A AR019415A1 AR 019415 A1 AR019415 A1 AR 019415A1 AR P990103510 A ARP990103510 A AR P990103510A AR P990103510 A ARP990103510 A AR P990103510A AR 019415 A1 AR019415 A1 AR 019415A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- procedure
- preparation
- piperidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
Abstract
Derivados de bifenilo de formula (1) en donde R representa -C(=NH)-NH2, -C(=NH)-NHA3, -C(=NH)-NHAc, -C(=NH) -NHSO2CH3, R2, -CO-NH-Z-R3 o -CO-R1, Xrepresenta -CONH-, SO2NH-, -NHCO- o -NHSO2, Y representa CH o N, A1 representa H, alquilo de 1 a 6 átomos de C en el cual 1 a 7 átomos de H pueden estarreeemplazados por F, SO2CH3, o SO2CF3, A2 representa H o alquilo de 1 a 6 átomos de C, A3, A5 representan independientemente alquilo C1-6, A6, A7representan independientemente H o (CH2)pCH3, Q representa H o OA1, R representa 4-A5-piperazin-1-ilo, 4-A5-homopiperazinilo, 1-pirrolidinilo monosustituidocon R4 o Z-R4, 1 piperidinilo monosustituido con R4 o Z-R4, N-A5-pirrolidinil-amino, N-A5-piperidinil-amino, N-A5-pirrolidinil-Z-amino, N-A5-piperidinil-Z-amino, -N(A6) (ZR3) o NA6A7, R2 representa 5-metil-1, 3, 4 -oxadiazol-2-ilo o 5- metil-1,2,4-oxadiazol-3-ilo, R3, R4 representan independientemente NHA5,N(A5)2, 4-morfolinilo, 1-pirrolidinilo o 1-piperidinilo, Z representa alquileno de 1 a 6 átomos de C, n es 0 o 1, p es 0, 1 o 2, con la condicion de que cuandoY representa N, X=CONH- y n=1, entonces R no es R2 o R no es -CONA6A7, incluyendo los racematos, los enantiomeros, las sales aceptables desde el punto de vistafisiologico y los solvatos de estos compuestos. Un procedimiento para preparar los compuestos de formula I, sus sales y sus solvatos, en el cual a) se hacereaccionar un compuesto de formula II en donde L representa Cl, Br, I o un grupo OH transformado funcionalmente en ungrupo reactivo, y R y A3 tienen lossignificados indicados más arriba, con un derivado del ácido boronico de formula III en donde X, Y, A1, A2 Q y n tienen los significados indicados más arriba ob) se hace reaccionar un compuesto de formula IV en donde R y A3 y L tienen los significados indicados, X representa CO o SO2, con un compuesto de formula Ven donde Y, A1, A2 y n tienen los significados indicados o c) para preparar un compuesto de formula I en donde R representa -CO-NH--Z-R3 o -CO-R1 se hacereaccionar un compuesto de formula VI en donde L representa Cl, Br, I o un grupo OH libre o transformado funcionalmente en un grupo reactivo, y X, Y, A1,A2, A3Biphenyl derivatives of formula (1) wherein R represents -C (= NH) -NH2, -C (= NH) -NHA3, -C (= NH) -NHAc, -C (= NH) -NHSO2CH3, R2, -CO-NH-Z-R3 or -CO-R1, X represents -CONH-, SO2NH-, -NHCO- or -NHSO2, Y represents CH or N, A1 represents H, alkyl of 1 to 6 C atoms in which 1 to 7 atoms of H may be replaced by F, SO2CH3, or SO2CF3, A2 represents H or alkyl of 1 to 6 atoms of C, A3, A5 independently represent C1-6 alkyl, A6, A7 independently represent H or (CH2) pCH3, Q represents H or OA1, R represents 4-A5-piperazin-1-yl, 4-A5-homopiperazinyl, 1-pyrrolidinyl monosubstituted with R4 or Z-R4, 1 piperidinyl monosubstituted with R4 or Z-R4, N-A5-pyrrolidinyl- amino, N-A5-piperidinyl-amino, N-A5-pyrrolidinyl-Z-amino, N-A5-piperidinyl-Z-amino, -N (A6) (ZR3) or NA6A7, R2 represents 5-methyl-1, 3 , 4-oxadiazol-2-yl or 5- methyl-1,2,4-oxadiazol-3-yl, R3, R4 independently represent NHA5, N (A5) 2,4-morpholinyl, 1-pyrrolidinyl or 1-piperidinyl, Z represents alkylene from 1 to 6 volumes of C, n is 0 or 1, p is 0, 1 or 2, with the proviso that when Y represents N, X = CONH- and n = 1, then R is not R2 or R is not -CONA6A7, including racemates , enantiomers, physiologically acceptable salts and solvates of these compounds. A process for preparing the compounds of formula I, their salts and their solvates, in which a) a compound of formula II is reacted wherein L represents Cl, Br, I or an OH group functionally transformed into a reactive group, and R and A3 have the meanings indicated above, with a boronic acid derivative of formula III where X, Y, A1, A2 Q and n have the meanings indicated above or b) a compound of formula IV is reacted where R and A3 and L they have the indicated meanings, X represents CO or SO2, with a compound of formula Ven where Y, A1, A2 and n have the meanings indicated oc) to prepare a compound of formula I wherein R represents -CO-NH-Z-R3 or -CO-R1 is reacted a compound of formula VI wherein L represents Cl, Br, I or a free or functionally transformed OH group in a reactive group, and X, Y, A1, A2, A3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98113488 | 1998-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019415A1 true AR019415A1 (en) | 2002-02-20 |
Family
ID=8232308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103510A AR019415A1 (en) | 1998-07-20 | 1999-07-16 | DERIVATIVES OF BIFENYLL, A PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT IN THE PREPARATION OF MEDICINES, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCEDURE TO PREPARE THESE PHARMACEUTICAL COMPOSITIONS |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1098892A1 (en) |
| JP (1) | JP2002521377A (en) |
| KR (1) | KR20010070997A (en) |
| CN (1) | CN1309654A (en) |
| AR (1) | AR019415A1 (en) |
| AU (1) | AU5033899A (en) |
| BR (1) | BR9912299A (en) |
| CA (1) | CA2338209A1 (en) |
| HU (1) | HUP0102622A3 (en) |
| ID (1) | ID27846A (en) |
| NO (1) | NO20010333D0 (en) |
| PL (1) | PL345283A1 (en) |
| SK (1) | SK492001A3 (en) |
| WO (1) | WO2000005225A1 (en) |
| ZA (1) | ZA200101379B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0115296A (en) * | 2000-11-14 | 2003-09-02 | Merck Patent Ges Mit Beschonkt | Use of combined sorotonin reuptake inhibitors and 5ht1a agonists |
| DE60122939T2 (en) | 2000-12-21 | 2007-01-11 | Nitromed, Inc., Bedford | SUBSTITUTED ARYL COMPOUNDS AS NEW, CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS, AND USE PROCESSES |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| CN1329382C (en) * | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | Novel arylsusfonamide compounds for treatment of obesity, type II diabetes and CNS-disorders |
| EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| SE0103644D0 (en) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
| BRPI0513713A (en) | 2004-07-28 | 2008-05-13 | Glaxo Group Ltd | piperazine derivatives useful for the treatment of gastrointestinal disorders |
| CN101039904B (en) * | 2004-10-14 | 2014-09-24 | Abbvie德国有限责任两合公司 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| WO2007077457A2 (en) * | 2006-01-06 | 2007-07-12 | The Royal Veterinary College | Treatment of equine laminitis with 5-ht1b/ 1d antagonists |
| AR060213A1 (en) | 2006-03-31 | 2008-06-04 | Glaxo Group Ltd | PIPERAZINIL COMPOUND - PIRIDINIL-BENCENSULFONAMIDE, ITS USE TO MANUFACTURE A MEDICINAL PROCESS FOR THE PREPARATION OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCESS TO PREPARE IT |
| US8497273B2 (en) | 2006-04-19 | 2013-07-30 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor |
| NZ572761A (en) | 2006-04-19 | 2011-09-30 | Abbott Gmbh & Co Kg | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
| CN101432261A (en) | 2006-05-19 | 2009-05-13 | 惠氏公司 | N-benzoyl-and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| NZ579766A (en) | 2007-03-23 | 2012-03-30 | Abbott Gmbh & Co Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| NZ581364A (en) | 2007-06-05 | 2011-10-28 | Nsab Af Neurosearch Sweden Ab | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
| AU2008258549B2 (en) | 2007-06-08 | 2013-11-14 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine/Piperazine derivatives |
| WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119920D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| ATE204262T1 (en) * | 1991-09-18 | 2001-09-15 | Glaxo Group Ltd | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS |
| GB2273930A (en) * | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| GB9507203D0 (en) * | 1995-04-07 | 1995-05-31 | Smithkline Beecham Plc | Novel compounds |
-
1999
- 1999-07-08 KR KR1020017000849A patent/KR20010070997A/en not_active Application Discontinuation
- 1999-07-08 SK SK49-2001A patent/SK492001A3/en unknown
- 1999-07-08 WO PCT/EP1999/004803 patent/WO2000005225A1/en not_active Application Discontinuation
- 1999-07-08 HU HU0102622A patent/HUP0102622A3/en unknown
- 1999-07-08 JP JP2000561181A patent/JP2002521377A/en active Pending
- 1999-07-08 CA CA002338209A patent/CA2338209A1/en not_active Abandoned
- 1999-07-08 PL PL99345283A patent/PL345283A1/en unknown
- 1999-07-08 BR BR9912299-5A patent/BR9912299A/en not_active Application Discontinuation
- 1999-07-08 EP EP99934632A patent/EP1098892A1/en not_active Withdrawn
- 1999-07-08 CN CN99808739A patent/CN1309654A/en active Pending
- 1999-07-08 ID IDW20010307A patent/ID27846A/en unknown
- 1999-07-08 AU AU50338/99A patent/AU5033899A/en not_active Abandoned
- 1999-07-16 AR ARP990103510A patent/AR019415A1/en not_active Application Discontinuation
-
2001
- 2001-01-19 NO NO20010333A patent/NO20010333D0/en unknown
- 2001-02-19 ZA ZA200101379A patent/ZA200101379B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1098892A1 (en) | 2001-05-16 |
| ID27846A (en) | 2001-04-26 |
| NO20010333L (en) | 2001-01-19 |
| HUP0102622A3 (en) | 2002-12-28 |
| NO20010333D0 (en) | 2001-01-19 |
| WO2000005225A1 (en) | 2000-02-03 |
| CA2338209A1 (en) | 2000-02-03 |
| HUP0102622A2 (en) | 2001-12-28 |
| ZA200101379B (en) | 2002-05-20 |
| BR9912299A (en) | 2001-11-20 |
| AU5033899A (en) | 2000-02-14 |
| CN1309654A (en) | 2001-08-22 |
| PL345283A1 (en) | 2001-12-03 |
| SK492001A3 (en) | 2001-08-06 |
| JP2002521377A (en) | 2002-07-16 |
| KR20010070997A (en) | 2001-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019415A1 (en) | DERIVATIVES OF BIFENYLL, A PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT IN THE PREPARATION OF MEDICINES, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCEDURE TO PREPARE THESE PHARMACEUTICAL COMPOSITIONS | |
| ATE40368T1 (en) | XANTHINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| IL66650A (en) | Dibenzoxepines and dibenzooxazepines,their preparation and pharmaceutical compositions containing them | |
| ATE107922T1 (en) | 2-(1-PIPERAZINYL)-4-PHENYLCYCLOALKANEPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| KR950008493A (en) | Adhesion receptor antagonist (III) | |
| ATE9793T1 (en) | 5-OXO- AND 5-THIOXOPROLINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| SE8404712L (en) | AZOLD DERIVATIVES, PROCEDURES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE | |
| FI832648A0 (en) | DIHYDROPYRIDINER SOM ANTIISCHEMISKA OCH ANTIHYPERTENSIVA CEILING MODEL | |
| ZA85390B (en) | Methylenediphosphonic acid derivatives,process for their preparation and antirheumatic pharmaceutical compositions in which they are present | |
| ATE5138T1 (en) | THIAZOLE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| MX9200485A (en) | PROCESS FOR OBTAINING DERIVATIVES OF TETRA HIDRO PIRIDINA AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM. | |
| SE9003973L (en) | GLYCEROL, A MANUFACTURING PROCEDURE FOR THE SAME AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | |
| ATE116647T1 (en) | THIOPHENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| SE8300855D0 (en) | NEW PIPERAZINE AND HOMOPIPERAZINE DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| IL81933A0 (en) | Asymmetrical ester derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid,their preparation and pharmaceutical compositions containing them | |
| ZA918991B (en) | Imidazole compounds,process for the preparation thereof and pharmaceutical compositions containing them | |
| PT83786A (en) | NEW BASIC SUBSTITUTED PYRIDINE COMPOUNDS METHOD FOR THE PRODUCTION THEREOF THE MEDICAMENT CONTAINING THEY AND THEIR USE | |
| ATE37368T1 (en) | BENZOTHIAZOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| GB2111056A (en) | Derivatives of 1, 4-thiazane-carboxylic acid preparation and utilization thereof and compositions containing same | |
| ATE52509T1 (en) | THIAZOLIDE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION. | |
| DE3168198D1 (en) | 4-thia and 4-sulfinyl pgi1 derivatives, their preparation and pharmaceutical compositions | |
| IE820160L (en) | Heterocyclic benzamide derivatives | |
| GB875955A (en) | Triphenylalkylamines and stimulant compositions containing them | |
| IL59358A0 (en) | Thiazole derivatives,their preparation and pharmaceutical compositions containing them | |
| ATE3041T1 (en) | 2-PENEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |